Vosevi Tablet, Film Coated
NDC Package 61958-2401-1
Package Information
Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) tablets is vOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration (2.2) and Clinical Studies (14)]:genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor. This formulation utilizes a tablet, film coated delivery system. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-2401 and is authorized under FDA application NDA209195.
Identification & Billing
- RxCUI: 1939329 - sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG Oral Tablet
- RxCUI: 1939335 - Vosevi 400 MG / 100 MG / 100 MG Oral Tablet
- RxCUI: 1939335 - sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG Oral Tablet [Vosevi]
- RxCUI: 1939335 - Vosevi 400/100/100 (sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG) Oral Tablet
- RxCUI: 1939335 - Vosevi 400/100/100 Oral Tablet
Clinical Specifications
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- HCV NS3/4A Protease Inhibitors - [MoA] (Mechanism of Action)
- Hepatitis C Virus NS3/4A Protease Inhibitor - [EPC] (Established Pharmacologic Class)
- Hepatitis C Virus NS5A Inhibitor - [EPC] (Established Pharmacologic Class)
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporting Polypeptide 1B3 Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporting Polypeptide 2B1 Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
- RNA Replicase Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 61958 - Gilead Sciences, Inc.
- 61958-2401 - Vosevi
- 61958-2401-1 - 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
- 61958-2401 - Vosevi
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61958-2401-1 identifies a specific commercial package of 28 tablet, film coated in 1 bottle, plastic of Vosevi, a human prescription drug labeled by Gilead Sciences, Inc.. This tablet, film coated is formulated for oral use and contains sofosbuvir; velpatasvir; voxilaprevir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gilead Sciences, Inc. on July 18, 2017. The current certification is valid through December 31, 2026.
How is this Gilead Sciences, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958240101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 28 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.